. Mechanism of rat mesenteric arterial K ATP channel activation by 14,15-epoxyeicosatrienoic acid.
ical functions, including gene expression, vasoreactivity, inflammation, cellular proliferation, hemostasis, and ischemic preconditioning (29, 32, 39) . In particular, considerable attention has been given to the role of EETs in mediating vasodilation through activation of K ϩ channels, serving as endothelium-derived hyperpolarizing factors (EDHFs) (1, 4, 7, 11) . EETs are known to stimulate the large-conductance Ca 2ϩ -activated K ϩ (BK) channels in coronary smooth muscle cells, producing membrane hyperpolarization and vasodilation (3, 14, 17) . The signaling mechanisms through which EETs exert their cellular effects in vascular smooth muscle cells remain unclear. Although circumstantial evidence exists regarding the presence of an EET-specific plasma membrane receptor, direct elucidation is lacking, and such a receptor has not been purified or cloned. Nevertheless, EETs have been shown to result in accumulation of intracellular cAMP (35, 36) , possibly through activation of the guanine nucleotide binding protein G s ␣ by ADP-ribosylation (18) . The EDHF activities of EETs were inhibited by the EET-specific antagonists 14,15-epoxyeicosa-5(Z)-enoic acid (14,15-EEZE) and 14,15-epoxyeicosa-5(Z)-enoic-methylsulfonylimide (14,15-EEZE-mSI), which are most effective in inhibiting the vasodilation and BK channel activation of 14,15-EET (6, 10, 12, 13) . These results indicate that there are specific structural requirements for EET activities, and such EET antagonists are useful tools in the investigation of EET functions.
ATP-sensitive potassium (K ATP ) channels are ubiquitous, linking cellular energy metabolic state to membrane excitability (28, 30, 38) . The cardiovascular system is richly endowed with K ATP channels, and vascular K ATP channels are thought to play an important role in the regulation of vascular tone (2) . Recently, we reported that rat mesenteric arterial K ATP channels are potently activated by all four EET regioisomers with an EC 50 of 87 nM for 11,12-EET (37) . Activation of K ATP channels accounts for ϳ50% of the mesenteric vasodilation by 11,12-EET, and these effects were dependent on protein kinase A (PKA) activities (37) . However, the signaling steps associated with the activation of vascular K ATP channels by EET are unclear. In this study, we hypothesized that ADP-ribosylation of G s ␣ is involved in the activation of mesenteric arterial K ATP channels by EETs. We found that activation of mesenteric arterial K ATP channels by 14,15-EET is blocked by 14,15-EEZE, anti-G s ␣ antibodies, and ADP-ribosyltransferase inhibitors. In addition, the effects of 14,15-EET on K ATP channels were mimicked by cholera toxin (CTX), an ADP-ribosyltransferase. These results were corroborated by vasoreactivity studies showing that 14,15-EET produced potent vasodilation in isolated small mesenteric arteries, and the effects of 14,15-EET were significantly attenuated by 14,15-EEZE and ADP-ribosyltransferase inhibitors. In addition, pinacidil-mediated K ATP channel activation and vasodilation were not inhibited by preincubation with 14,15-EEZE and ADP-ribosyltransferase inhibitors or by inclusion of anti-G s ␣ antibody in the patch pipette solution, suggesting that the effects of these compounds are specific, inhibiting steps in the EET signaling pathway that results in K ATP channel activation. These findings suggest that activation of vascular K ATP channels by EET involves ADPribosylation of G s ␣.
MATERIALS AND METHODS
Isolation of arterial smooth muscle cells from rat small mesenteric arteries. The use of animals and procedures involved with tissue isolation were approved by the Animal Care and Use Committee at the Mayo Clinic (Rochester, MN). Single vascular smooth muscle cells were prepared as previously described (37) . Briefly, male Sprague-Dawley rats (200 -250 g) were anesthetized with pentobarbital sodium (100 mg/kg ip). Bowels and mesenteries were rapidly excised and placed in Krebs solution that contained (in mM) 118.3 NaCl, 4.7 KCl, 2.5 CaCl 2, 1.2 MgSO4, 1.2 KH2PO4, 25 NaHCO3, 11.1 dextrose, equilibrated with 5% CO2-95% room air. The thirdand fourth-ordered branches (100 -250 m in intraluminal diameter) of mesenteric arteries were isolated and placed in 1 ml of physiological saline solution that contained (in mM) 145 NaCl, 4.0 KCl, 0.05 CaCl 2, 1.0 MgCl2, 10.0 HEPES, 10.0 glucose, pH 7.2, with 0.1% BSA. After incubation at room temperature for 10 min, vessels were enzymatically dissociated as previously described (37) . The resulting smooth muscle cell suspension was stored at 4°C and used within 8 h.
Whole cell patch-clamp recordings. Whole cell currents were recorded from single smooth muscle cells by using patch-clamp techniques as previously described (21, 37) . Isolated smooth muscle cells were placed in a recording chamber on the stage of an inverted microscope and were superfused with an extracellular bath solution that contained (in mM) 140 KCl, 1 MgCl 2, 0.1 CaCl2, 10 HEPES, 10 glucose, pH 7.4, at 1-2 ml/min, and solution exchanges were complete within 30 -60 s. Whole cell K ATP currents were recorded with a pipette solution that contained (in mM) 110 KCl, 30 KOH, 10 HEPES, 10 EGTA, 1 MgCl2, 1 CaCl2, 0.1 or 1 Na2ATP, 0.1 Na2ADP, 0.5 Na 2GTP, pH 7.4, by using an Axopatch 200 integrating amplifier (Axon Instruments, Foster City, CA); filtered at 1 kHz; and sampled at 5 kHz. Pipette resistance ranged from 3 to 5 M⍀, and seal resistance was Ͼ10 G⍀. pCLAMP 8.0 software (Axon) was used for generating voltage-clamp protocols and for acquisition and analysis of KATP currents. Currents were elicited with a holding potential (HP) of 0 mV, and pulsing from Ϫ100 to 40 mV in increments of 10 mV. KATP currents were obtained by digital subtraction of the residual currents after exposure to glibenclamide (10 M). The glibenclamidesensitive K ϩ currents were determined and referred to as KATP currents. All cellular electrophysiology experiments were performed at room temperature (21-23°C). To minimize the activity of BK channels, intracellular Ca 2ϩ was buffered by EGTA to low levels (ϳ20 nM). In addition, 100 nM of iberiotoxin (IBTX) was present in the bath solution to block BK channel activities that could be activated by EETs (21, 37 Vasoreactivity measurements. Vasoreactivity of isolated small mesenteric arteries (100 -250 m in diameter) was determined by videomicroscopy as previously described (37, 40) . Isolated small mesenteric arteries (1-2 mm in length) were transferred to a vessel chamber filled with Krebs solution, cannulated with micropipettes, and pressurized at 60 mmHg for at least 30 min at 37°C before starting the experiment. In some experiments, vessels were incubated with 14,15-EEZE (10 M), 14,15-EEZE ϩ glibenclamide (1 M), or 3-aminobenzamide (3-AB, 1 mM) for 30 -45 min during the equilibration period. 14,15-EET or 14,15-EEZE was added abluminally, and the cumulative dose response was determined at 3-to 5-min intervals between doses. Vessels were constricted to 30 -60% of baseline diameter using endothelin-1, and the effects of 14,15-EET in dilating these vessels were examined over the concentration range of 1 ϫ 10 Ϫ10 to 1 ϫ 10 Ϫ6 M. In some control experiments, pinacidil (10 Ϫ7 to 10 Ϫ5 M) was used as the vasodilator to determine the specificity of the 14,15-EEZE and 3-AB effects. Vessels were discarded if they failed to produce an 85% relaxation with 1 ϫ 10 Ϫ4 M sodium nitroprusside or failed to produce a 30% constriction with 60 mM KCl.
Materials. 14,15-EET was obtained from Cayman Chemical (Ann Arbor, MI), solubilized in ethanol as a 5 mM stock, and stored at Ϫ80°C. 14,15-EEZE was solubilized in ethanol as a 10 mM stock, and stored at Ϫ20°C. Glibenclamide and 3-AB were solubilized in DMSO, while m-iodobenzylguanidine (MIBG) was solubilized in methanol. The rest of the chemicals were solubilized in water. CTX and anti-G s␣ antibody were obtained from Calbiochem (San Diego, CA). Control IgG was obtained from Santa Cruz Biotechnology (Santa Cruz, CA). 3-AB, MIBG, glibenclamide, and IBTX were obtained from Sigma Chemical (St. Louis, MO).
Statistical analysis. All data are expressed as means Ϯ SE. Oneway ANOVA was used to analyze data from multiple groups, and pairwise comparisons among groups were performed using a post hoc Tukey test. Student's paired t-test was used to compare data before and after each intervention. Statistically significant difference is defined as P Ͻ 0.05.
RESULTS

Activation of vascular K ATP currents by 14,15-EET is inhibited by 14,15-EEZE.
Rat mesenteric artery smooth muscle cells exhibited very little glibenclamide-sensitive K ϩ currents (K ATP currents) under baseline condition. With 0.1 mM ATP in the pipette, 140 mM symmetrical K ϩ , holding at 0 mV, and pulsing to Ϫ100 mV, the K ATP current amplitude was 19.0 Ϯ 7.9 pA (n ϭ 5, Fig. 1A ). 14,15-EET at 5 M produced a 6.9-fold activation of K ATP currents (132.0 Ϯ 29.0 pA, n ϭ 7, P Ͻ 0.05 vs. control, Fig. 1B ). However, after incubation with 5 M 14,15-EEZE, an EET-specific antagonist, the effects of 14,15-EET were significantly attenuated [31.0 Ϯ 11.8 pA, n ϭ 5, P Ͻ 0.05 vs. 14,15-EET and P ϭ nonsignificant (NS) vs. control, Fig. 1C ]. Figure 1D shows the current-voltage (I-V) relationships of the effects of 14,15-EET and 14,15-EEZE on K ATP currents. 14,15-EET activated K ATP currents over the full voltage range examined. Likewise, the inhibitory effects of 14,15-EEZE were independent of membrane potential. Figure  1E shows group data in bar graphs on K ATP currents elicited at Ϫ100 mV. These results suggest that 14,15-EET as a vascular K ATP channel activator may have specific cellular binding sites, where its structural analog competes for binding and antagonizes its activities. 
G s ␣ is required for 14,15-EET-induced activation of K ATP channels.
To investigate whether G s ␣ is involved in the activation of K ATP channels by 14,15-EET, we used an anti-G s ␣ antibody in the pipette solution to inhibit the effect of G s ␣. We have previously used this approach in determining the PKAindependent, direct membrane delimiting effects of G s ␣ on cardiac Na ϩ channel activation (22, 24) . With anti-G s ␣ (1:500 dilution) in the pipette, holding at 0 mV and pulsing to Ϫ100 mV, K ATP current activation by 14,15-EET was significantly inhibited at 44.0 Ϯ 14.2 pA (n ϭ 6, P Ͻ 0.05 vs. 14,15-EET). In contrast, with control IgG (1:500 dilution) in the pipette, the stimulatory effects of 5 M 14,15-EET remained intact (118.6 Ϯ 24.3 pA, n ϭ 5, P Ͻ 0.05 vs. control) (Fig. 2, A-E) . The I-V relationships of K ATP current activation by 5 M 14,15-EET with no antibody, with anti-G s ␣ antibody, or with control IgG in the pipette solution are shown in Fig. 2F . The effects of 14,15-EET were significantly blocked by anti-G s ␣ antibody at all negative potentials (n ϭ 6, P Ͻ 0.05 vs. EET), while control IgG had no effect (n ϭ 5, P Ͻ 0.05 vs. control and vs. EET ϩ anti-G s ␣). These results suggest that G s ␣ is critically involved in the activation of K ATP channels by 14,15-EET.
K ATP channel activation by 14,15-EET is mediated through ADP-ribosyltransferase.
To study the role of ADP-ribosylation in the activation of vascular K ATP channels by 14,15-EET, we examined the effects of CTX, an exogenous ADP-ribosyltransferase, on K ATP channel activation. With 100 ng/ml CTX in the pipette solu- tion, K ATP currents were significantly activated after pipette breakthrough in the whole cell configuration. At baseline, mesenteric smooth muscle cells had only a small amount of K ATP currents (11.4 Ϯ 3.4 pA, n ϭ 5) that showed a 10.2-fold increase after treatment with CTX (116.2 Ϯ 19.6 pA, n ϭ 5, P Ͻ 0.05 vs. baseline) and that achieved a similar level of current activation by 5 M 14,15-EET (105.5 Ϯ 15.9 pA, n ϭ 5, P Ͻ 0.05 vs. baseline, P ϭ NS vs. CTX). After CTX effects had reached steady state, subsequent exposure to 5 M 14,15-EET did not produce further K ATP current increase (112.8 Ϯ 29.7 pA, n ϭ 5, P Ͻ 0.05 vs. baseline, P ϭ NS vs. CTX). Figure 3 , A-D, shows typical current tracings at baseline, with 5 M 14,15-EET, CTX, and CTX ϩ 14,15-EET. Group data are shown in Fig. 3E . These results suggest that ADP-ribosylation of G s ␣ may be involved in the activation of vascular K ATP channels by 14,15-EET.
To further confirm that ADP-ribosylation is involved in K ATP channel activation by 14,15-EET, we examined the effects of two different inhibitors of mono-ADP-ribosyltransferases, 3-AB (27) and MIBG (10, 17, 27) . Treatment with 1 mM 3-AB (n ϭ 6) or 100 M MIBG (n ϭ 5) did not affect the basal K ATP channel activities (P ϭ NS vs. control). However, after incubation with 3-AB, the stimulatory effects of 5 M 14,15-EET were abolished (13.6 Ϯ 12.3 pA at baseline and 25.9 Ϯ 17.3 pA with 14,15-EET, n ϭ 6, P ϭ NS). Similarly, treatment with 100 M MIBG abrogated the effects of 14,15-EET (19.1 Ϯ 3.8 pA at baseline and 21.1 Ϯ 7.8 pA with 14,15-EET, n ϭ 5, P ϭ NS) (Fig. 4) . These results suggest that K ATP channel activation by 14,15-EET is mediated through ADP-ribosylation of G s ␣.
14,15-EET hyperpolarizes the membrane potentials of mesenteric smooth muscle cells through activation of K ATP channels. To determine the physiological relevance of vascular K ATP channel activation by EETs, we examined the 14,15-EET effects in the presence of millimolar concentrations of cytoplasmic ATP. With 1 mM ATP in the pipette solution, K ATP currents were activated by 1 M 14,15-EET (Fig. 5, A and B) . Figure 5C shows I-V relationships of the effects of 14,15-EET on K ATP currents. 14,15-EET at 1 M significantly activated K ATP currents from Ϫ100 to Ϫ70 mV. Figure 5D shows group data in bar graphs. The K ATP current amplitudes (HP at 0 mV, testing potential at Ϫ100 mV) were 16.2 Ϯ 6.5 pA at baseline (n ϭ 9), and 1 M 14,15-EET produced a 3.5-fold activation of K ATP currents (57.5 Ϯ 14.3 pA, n ϭ 9, P Ͻ 0.05 vs. baseline). These results suggest that 14,15-EET is capable of activating vascular K ATP channels in the presence of millimolar concentration of ATP.
To further determine the physiological relevance of these findings, we measured the effects of 14,15-EET on the membrane potentials of mesenteric smooth muscle cells using whole cell current-clamp technique at 37°C, in the presence of 5 mM cytoplasmic ATP and 200 nM free Ca 2ϩ . To minimize the effects of EETs on BK channels, 100 nM of IBTX was present in the bath solution. Figure 6A shows recordings from a representative experiment. Figure 6B shows group data in bar graphs. The mesenteric smooth muscle cell membrane potential was hyperpolarized by 1 M 14,15-EET from Ϫ20.5 Ϯ 0.9 mV at baseline to Ϫ27.1 Ϯ 3.0 mV (n ϭ 6, P Ͻ 0.05 vs. baseline). Addition of 10 M glibenclamide significantly reversed the effects of 14,15-EET with membrane potentials at Ϫ21.8 Ϯ 1.4 mV (n ϭ 6, P Ͻ 0.05. vs. EET). These results indicate that 14,15-EET can hyperpolarize the membrane potentials of vascular smooth muscle cells through activation of K ATP channels in the presence of 5 mM cytoplasmic ATP.
Vasodilation of small mesenteric arteries by 14,15-EET is mediated through K ATP channel activation and ADP-ribosylation of G s ␣.
To further determine the mechanism of rat mesenteric artery vasodilation by 14,15-EET, we examined the effects of 14,15-EEZE, glibenclamide and 3-AB on 14,15-EET-induced vasodilation. 14,15-EET produced potent dosedependent dilation of small mesenteric arteries: 3.2 Ϯ 0.5% at 10 Ϫ10 M, 13.4 Ϯ 2.1% at 10 Ϫ9 M, 35.8 Ϯ 6.7% at 10 Ϫ8 M, 55.8 Ϯ 4.0% at 10 Ϫ7 M, and 73.8 Ϯ 2.0% dilation at 10 Ϫ6 M (n ϭ 5). These values were similar to those previously reported in rat mesenteric arteries (25) and in bovine coronary arteries (6) . The corresponding vessel diameter changes at these 14,15-EET concentrations were 2.0 Ϯ 0.1, 8.6 Ϯ 0.9, 22.4 Ϯ 1.1, 36.7 Ϯ 2.1, and 49.6 Ϯ 4.7 m, respectively (Fig. 7) . Treatment with 10 M 14,15-EEZE for 30 -45 min significantly attenuated the vasodilatory effects of 14,15-EET, with 1 M 14,15-EET producing only 22.2 Ϯ 3.8% dilation with vessel diameter change of 14.4 Ϯ 2.8 m, a 70% reduction (n ϭ 5, P Ͻ 0.001 vs. control for all doses). Incubation with both 14,15-EEZE and glibenclamide had no additional diminution of the EET effects, with 1 M 14,15-EET producing 25.4 Ϯ 1.0% dilation and vessel diameter changes of 16.5 Ϯ 2.4 m (n ϭ 5, P Ͻ 0.001 vs. control for all doses, P ϭ NS vs. 14,15-EEZE). In comparison, 14,15-EEZE itself had very little vasodilation effect, with 1 M 14,15-EEZE producing 7.9 Ϯ 1.1% dilation and vessel diameter changes of 4.6 Ϯ 0.4 m (n ϭ 5, P Ͻ 0.001 vs. 14,15-EET). These results indicate that 14,15-EEZE inhibited all the K ATP -mediated vasodilation effects by 14,15-EET. After incubation with 1 mM 3-AB, vasodilation to 14,15-EET was also significantly attenuated, with 1 M 14,15-EET producing only 31.6 Ϯ 4.7% dilation and vessel diameter changes of 14.6 Ϯ 1.7 m (n ϭ 6, P Ͻ 0.001 vs. control), similar to the level of inhibition by 14,15-EEZE. These results indicate that mono-ADP-ribosyltransferase activities are crucial in mediating the EET-mediated vasodilation.
Activation of K ATP channels by pinacidil is not inhibited by 14,15-EEZE, 3-AB, MIBG, or anti-G s ␣ antibody.
To demonstrate that the inhibitors used in this study exert specific effects on the EET signaling pathway, we examined their effects on K ATP channel activation by pinacidil. In isolated mesenteric smooth muscle cells, K ATP current activation by 10 M pinacidil was not inhibited by preincubation with 5 M 14,15-EEZE, 1 mM 3-AB, 100 M MIBG, or by inclusion of anti-G s ␣ antibody (1:500 dilution) in the pipette solution (Fig. 8A) . Similarly, vasodilation in rat small mesenteric arteries produced by pinacidil (10 Ϫ7 to 10 Ϫ5 M) was not inhibited by preincubation with 1 mM 3-AB or 10 M 14,15-EEZE (Fig.  8B) . These results indicate that the drugs used do not inhibit K ATP channel directly nor do they interfere with the action of pinacidil, which activates the channel through direct binding. Hence, the effects of 14,15-EEZE, 3-AB, MIBG, and anti-G s ␣ antibody are specific, inhibiting EET-mediated signaling steps. The results of these control experiments provide further support that the activation of vascular K ATP channels by 14,15-EET is mediated through structural specific activation of the PKA cascade involving G s ␣ ribosylation. 
DISCUSSION
The important observations from this study include the following. First, we found that 14,15-EEZE, a specific EET antagonist, inhibited activation of rat mesenteric arterial K ATP channels by 14,15-EET. Second, activation of K ATP channels by 14,15-EET was inhibited by anti-G s ␣ antibody. Third, inhibitors of mono-ADP-ribosyltransferase were effective in abrogating the effects of 14,15-EET on K ATP channels. Fourth, 14,15-EET-mediated vasodilation was also significantly diminished by 14,15-EEZE and by 3-AB. Fifth, in the presence of physiological concentrations of ATP, 14,15-EET hyperpolarized smooth muscle membrane potentials through K ATP channel activation. These results suggest that activation of K ATP channels by 14,15-EET involves a specific EET binding site and is dependent on the integrity of G s ␣ and mono-ADPribosyltransferase activities. These findings are consistent with the mechanism in which EETs bind to a specific site or receptor to facilitate ADP-ribosylation of G s ␣, leading to activation of vascular K ATP channels and membrane hyperpolarization, which in turn results in vasodilation.
We have previously reported that EETs are potent activators of cardiac and vascular K ATP channels with EC 50 in the range of 1 ϫ 10 Ϫ8 M (20, 23, 37). However, there are important differences between the mechanisms by which EETs activate cardiac and vascular K ATP channels. EETs directly activate cardiac K ATP channels, without the presence of any diffusible second messengers, by reducing the channel sensitivity to ATP (20, 23) . Interaction between EET and cardiac K ATP channels is stereospecific with 11(S),12(R)-EET being the active enantiomer while 11(R),12(S)-EET is totally inactive (23) . Recently, we have identified R192/R195 on Kir6.2, which encodes cardiac K ATP channels, as the critical EET sensitivity site (19) . In contrast, we found that activation of vascular K ATP channels by EET is mediated by PKA-dependent mechanisms (37). The signaling steps through which extracellular EET activates PKA is not clear, because the presence of an EETspecific cell surface receptor in vascular smooth muscle cells has not been directly identified.
In this study, we found that 14,15-EEZE completely abolished the activation of vascular K ATP channels by 14,15-EET, suggesting that the action of EET is mediated through a specific binding site and not through nonspecific fatty acid or lipid effects. The presence of a cell surface EET receptor site was first proposed by Wong et al., who demonstrated high affinity binding sites for 14,15-EET in the plasma membrane of human U-937 transformed monocytes (35) and in guinea pig . C: I-V relationships of KATP (glibenclamide sensitive) currents at baseline (n ϭ 9) and with 1 M 14,15-EET (n ϭ 9). D: bar graphs showing group data on KATP currents elicited from a holding potential of 0 mV and a testing potential of Ϫ100 mV at baseline (n ϭ 9), with 1 M 14,15-EET (n ϭ 9). *P Ͻ 0.05 vs. baseline. mononuclear cells (34) . In both cases, the putative receptor was linked to a cAMP and PKA signal transduction pathway that subsequently downregulates the receptor. In addition, structural analogs of EETs, such as 14,15-EEZE and 14,15-EEZEmSI, showed regioisomer-specific antagonist activities in coronary arteries, indicating precise structural requirements for 14,15-EET functions, including K ϩ channel activation and vasodilation (6, 10, 12, 13) . Recently, cAMP-induced aromatase activities in cultured aortic smooth muscle cells were found to be inhibited by 14,15-EET, by the nonmetabolized N-methylsulfanilamide derivative of 14,15-EET (14,15-EET-SI), and by the membrane impermeable 14,15-EET-SI that was covalently tethered to silica beads. These results suggest the presence of a specific EET binding site, possibly a receptor, in the plasma membrane (31) . The results of our study lend support to the growing evidence that an EET receptor might be present in the plasma membrane of smooth muscle cells and is involved in the activation of K ATP channels in vascular smooth muscle cells (10, 31, 32) .
EETs have also been shown to affect cell membrane signaling mechanisms, including ADP-ribosylation (18), G s ␣-mediated responses (9, 18) , activation of PKA (15) , and tyrosine phosphorylation (5) . The effects of EET on ADP-ribosylation and G s ␣, in particular, are thought to underlie the activation of BK channels (9, 17, 18) . In this study, we found that the effects of 14,15-EET on K ATP channels were inhibited by the inclu- Ϫ10 to 1 ϫ 10 Ϫ6 M) was determined after incubation with no drug (■; control, n ϭ 5), with 10 M 14,15-EEZE (F, n ϭ 5), 10 M 14,15-EEZE ϩ 1 M glibenclamide (OE, n ϭ 5), and 1 mM 3-AB (, n ϭ 6). 14,15-EEZE alone (ᮀ, n ϭ 5, 1 ϫ 10 Ϫ10 to 1 ϫ 10 Ϫ6 M) had very little dilatory effect on small mesenteric arteries. Data are presented as means Ϯ SE; P Ͻ 0.001 for all groups vs. control. sion of anti-G s ␣ antibody but not by control IgG in the pipette solution. We have used similar approaches to determine the direct G s ␣ effects on cardiac Na ϩ channel activation (22, 24) . Our results indicate that activation of vascular K ATP channels requires the integrity of G s ␣ activities. In addition, CTX, an exogenous ADP-ribosyltransferase that is well known to target G s ␣, produces remarkable activation of the K ATP currents in the mesenteric smooth muscle cells, enhancing the currents to a similar level attained by 14,15-EET. Exposure to 14,15-EET in the presence of CTX did not produce any further K ATP current stimulation, suggesting that CTX and EET might share a similar mechanism of action in K ATP channel activation. These results are similar to those reported on BK channel activation by EET in vascular smooth muscle cells (9, 17) and suggest that ADP-ribosylation of G s ␣ might be responsible for the activation of vascular K ATP channels by EETs. This contention is supported by the finding that the effects of 14,15-EET were inhibited by two different mono-ADP-ribosyltransferase inhibitors, 3-AB and MIBG, suggesting that ADPribosylation is involved in the signaling mechanism through which 14,15-EET activates vascular K ATP channels. Because the G protein signaling cascades are typically activated through interaction with G protein-coupled receptors that characteristically have a structural motif of seven transmembrane domains, it is plausible that EETs also exert their effects in vascular smooth muscle through similar receptor-dependent interactions (12) . EETs have been shown to enhance the GTP-binding activities of G s ␣ by 3.5-fold and to increase intracellular cAMP concentration in cultured endothelial cells (26) , cardiac myocytes (36), U-937 cells (35) , guinea pig mononuclear cells (34) , cerebral microvascular cells (16) , and vascular smooth muscle cells (33) . The increase in cAMP would then activate PKA, enhancing K ATP channel activities.
Physiological relevance of the observation in single smooth muscle cells is corroborated by vasoreactivity studies. 14,15-EEZE produced very little vasodilation but was an ardent inhibitor to that produced by 14,15-EET. These results are similar to studies using small bovine coronary arteries (10) . We have previously shown that activation of K ATP channels accounts for ϳ50% of the vasodilation effects of EETs (37) . In the present study, addition of glibenclamide to 14,15-EEZE had no additional inhibitory effect, suggesting 14,15-EEZE was effective in totally inhibiting the K ATP channel activation component of vasodilation induced by 14,15-EET. In addition, incubation with 3-AB also produced significant inhibition of the 14,15-EET vasodilatory effects, indicating that ADP-ribosylation is a critical step in mediating the effects of 14,15-EET. The effects of the inhibitors 14,15-EEZE, 3-AB, MIBG, and anti-G s ␣ antibody are specific in inhibiting the EET signaling steps, and they do not inhibit the effects of pinacidil on K ATP channels or on vasodilation (Fig. 8) . Evidently, activation of K ATP channels through EET-induced ADP-ribosylation of G s ␣ is an integral mechanism for regulating vasoreactivity.
Previous studies from several laboratories have shown that EETs serve as EDHF in coronary and other circulations (1, 4, 7, 11) . EETs are potent activators of vascular BK channels, producing membrane hyperpolarization, leading to vasorelaxation (3, 14, 17) , suggesting that BK channels play a critical role in EETs-induced vasodilation. Fukao et al. (8) reported that 11,12-EET-induced smooth muscle hyperpolarization in isolated rat mesenteric arteries was blocked by glibenclamide, suggesting that K ATP channels were involved. Recently, we have reported that 11,12-EET potently activates rat mesenteric arterial K ATP channels and produces vasorelaxation (37) . In the present study, we found that under physiological conditions, 14,15-EET produces membrane hyperpolarization in rat mesenteric smooth muscle cells through activation of K ATP channels. These findings confirm that activation of vascular K ATP channels is an important component in mediating the vasodilatory effects of EETs.
In summary, a specific scheme on the signaling mechanism with which EETs activate vascular K ATP channels has emerged. On the basis of the results from our current and previous studies, we propose that EETs interact with specific binding sites or receptors in vascular smooth muscle cells, leading to activation of G s ␣ through ADP-ribosylation. This results in activation of adenylyl cyclase activities, promoting the formation of cAMP, which in turn activates PKA. PKA phosphorylates and activates vascular K ATP channels, producing membrane hyperpolarization and vasodilation.
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